Shares of IDEAYA Biosciences (NASDAQ:IDYA) have been given an average recommendation of “Buy” by the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $18.00.
A number of equities analysts have recently commented on IDYA shares. Roth Capital started coverage on shares of IDEAYA Biosciences in a report on Friday, March 13th. They issued a “buy” rating and a $12.00 price target on the stock. Zacks Investment Research cut shares of IDEAYA Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 18th. Finally, ValuEngine raised shares of IDEAYA Biosciences from a “hold” rating to a “buy” rating in a research note on Tuesday, March 3rd.
Institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC purchased a new stake in shares of IDEAYA Biosciences in the 3rd quarter valued at $118,000. Point72 Asset Management L.P. boosted its stake in shares of IDEAYA Biosciences by 1.0% in the 3rd quarter. Point72 Asset Management L.P. now owns 197,615 shares of the company’s stock valued at $1,779,000 after purchasing an additional 2,048 shares in the last quarter. 5AM Venture Management LLC purchased a new stake in shares of IDEAYA Biosciences in the 4th quarter valued at $25,973,000. Alambic Investment Management L.P. purchased a new stake in shares of IDEAYA Biosciences in the 4th quarter valued at $148,000. Finally, Canaan Partners X LLC purchased a new stake in shares of IDEAYA Biosciences in the 4th quarter valued at $19,955,000. 51.16% of the stock is owned by institutional investors.
IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Tuesday, March 24th. The company reported ($0.53) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.04. As a group, equities research analysts predict that IDEAYA Biosciences will post -2.28 earnings per share for the current year.
About IDEAYA Biosciences
IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
Further Reading: Should You Consider an Index Fund?
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.